ImmuCell Corporation (ICCC) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ICCC Revenue Growth
Revenue Breakdown (FY 2021)
ICCC's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
By Geography
ICCC Revenue Analysis (2013–2024)
As of May 8, 2026, ImmuCell Corporation (ICCC) generated trailing twelve-month (TTM) revenue of $27.8 million, reflecting moderate decline in growth of -8.4% year-over-year. The most recent quarter (Q3 2025) recorded $5.5 million in revenue, down 14.6% sequentially.
Looking at the longer-term picture, ICCC's 5-year compound annual growth rate (CAGR) stands at +14.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $26.5 million in 2024, representing a new all-time high.
Revenue diversification analysis shows ICCC's business is primarily driven by FirstDefenseProductLineMember (98%), and OtherAnimalHealthMember (2%). With over half of revenue concentrated in FirstDefenseProductLineMember, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PCRX (+4.6% YoY), NEOG (-3.7% YoY), and PAHC (+32.4% YoY), ICCC has underperformed the peer group in terms of revenue growth. Compare ICCC vs PCRX →
ICCC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ICCCCurrent | $28M | -8.4% | +14.1% | -6.2% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 NEOG | $895M | -3.7% | +16.4% | 1.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 ELAN | $4.7B | +10.5% | +7.6% | 5.3% | |
 PETZ | $1M | -71.1% | +15.0% | -146.3% |
ICCC Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $26.5M | +51.6% | $7.9M | 30.0% | $-1,640,159 | -6.2% |
| 2023 | $17.5M | -5.9% | $4.4M | 25.2% | $-5,748,078 | -32.9% |
| 2022 | $18.6M | -3.5% | $7.6M | 41.2% | $-2,299,000 | -12.4% |
| 2021 | $19.2M | +25.4% | $8.7M | 45.0% | $257K | 1.3% |
| 2020 | $15.3M | +11.8% | $6.9M | 44.7% | $-1,380,000 | -9.0% |
| 2019 | $13.7M | +24.9% | $6.7M | 49.1% | $-954,000 | -7.0% |
| 2018 | $11.0M | +5.3% | $5.2M | 47.3% | $-1,447,000 | -13.2% |
| 2017 | $10.4M | +9.3% | $5.2M | 50.1% | $-243,000 | -2.3% |
| 2016 | $9.5M | -6.7% | $5.4M | 56.8% | $890K | 9.3% |
| 2015 | $10.2M | +34.6% | $6.3M | 61.1% | $2.1M | 20.7% |
See ICCC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ICCC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ICCC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonICCC — Frequently Asked Questions
Quick answers to the most common questions about buying ICCC stock.
Is ICCC's revenue growth accelerating or slowing?
ICCC revenue declined -8.4% year-over-year, contrasting with the 5-year CAGR of +14.1%. TTM revenue fell to $28M. This reverses the prior growth trend.
What is ICCC's long-term revenue growth rate?
ImmuCell Corporation's 5-year revenue CAGR of +14.1% reflects the variable expansion pattern. Current YoY growth of -8.4% is below this long-term average.
How is ICCC's revenue distributed by segment?
ICCC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.